Physician profile
Heather S Luing
NPI 1952477366
$1,457,488.09
in general payments reported to CMS, 2019-2025
22 companies · $403K in 2025
The $403K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122K · 2020: $71K · 2021: $129K · 2022: $225K · 2023: $275K · 2024: $233K · 2025: $403K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $550K · Consulting Fee: $124K · Honoraria: $111K · Travel and Lodging: $102K · Food and Beverage: $23K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $550,338.00 |
| Consulting Fee | $123,986.50 |
| Honoraria | $111,487.75 |
| Travel and Lodging | $102,006.71 |
| Food and Beverage | $23,184.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $534,147.26 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Janssen Pharmaceuticals, INC | $334,877.46 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $225,134.52 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $183,498.94 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $59,013.50 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $55,000.32 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $42,350.14 | 2024-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $15,512.72 | 2022-2025 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $4,525.05 | 2022-2025 | Abilify Maintena, Rexulti, Rejoyn |
| Biogen, INC. | $1,534.99 | 2023 | |
| Livanova USA, INC. | $568.13 | 2021 | |
| Abbvie INC. | $417.16 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $400.00 | 2024-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $163.95 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $124.99 | 2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $74.12 | 2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $64.79 | 2019 | |
| Sage Therapeutics, LLC | $28.76 | 2025 | Zurzuvae |
| Bausch Health US, LLC | $20.94 | 2025 | Aplenzin |
| Collegium Pharmaceutical, INC. | $18.43 | 2025 | Jornay Pm |
| Uswm, LLC | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Luing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.